



ERIC HOLCOMB, GOVERNOR
STATE OF INDIANA

Office of Medicaid Policy and Planning
MS 07, 402 W. WASHINGTON STREET, ROOM W382
INDIANAPOLIS, IN 46204-2739

MEETING AGENDA AND PUBLIC NOTIFICATION

Therapeutics Committee
February 7, 2020
9:00 A.M.

Conference Center Room "A"

Indiana State Government Center South

1. Call to Order-Chair
2. Opening Comments-OMPP
3. Approval of Memoranda, Meeting of November 1, 2019
4. Election of Officers - CY2020
5. Preferred Drug List: Therapeutic Class Re-Review
 - a) Respiratory
 - i. Antihistamine-Decongestant Combinations/2nd Generation Antihistamines
 - ii. Antiviral Monoclonal Antibodies
 - iii. Beta Adrenergics and Corticosteroids
 - iv. Beta Agonists
 - v. Bronchodilator Agents - Beta Adrenergic and Anticholinergic Combinations
 - vi. Leukotriene Receptor Antagonists
 - vii. Monoclonal Antibodies for the Treatment of Respiratory Conditions
 - viii. Nasal Antihistamines/Nasal Anti-Inflammatory Steroids



- ix. Oral Inhaled Glucocorticoids
- x. Phosphodiesterase-4 Inhibitors
- xi. Pulmonary Antihypertensives
- b) Anti-Infectives
 - i. Antivirals - Anti-Herpetic Agents
 - ii. Antivirals - Influenza Agents
 - iii. Cephalosporins - 3rd Generation
 - iv. Fluoroquinolones
 - v. Hepatitis C Agents
 - vi. Macrolides
 - vii. Ophthalmic Antibiotics
 - viii. Ophthalmic Antibiotics/Corticosteroid Combinations
 - ix. Oral Non-Systemic Antifungals
 - x. Otic Antibiotics
 - xi. Systemic Antifungals
 - xii. Topical Antifungals
 - xiii. Topical Antivirals
 - xiv. Topical Antivirals and Anti-Inflammatory Steroid Combinations
 - xv. Vaginal Antimicrobials
- c) Cardiovascular
 - i. Angiotensin-Converting Enzyme (ACE) Inhibitors
 - ii. ACE Inhibitor Combinations
 - iii. Alpha Adrenergic Blockers
 - iv. Angiotensin II Receptor Antagonists (ARBs)
 - v. ARB Combinations
 - vi. Beta Adrenergic Blockers
 - vii. Beta Adrenergic Blockers with Diuretics
 - viii. Calcium Channel Blockers (CCBs)
 - ix. CCBs with HMG-CoA Reductase Inhibitors
 - x. Miscellaneous Cardiac Agents
- d) Lipotropics

- i. Bile Acid Sequestrants
 - ii. Fibric Acid Derivatives
 - iii. HMG-CoA Reductase Inhibitors
 - iv. Lipotropics
 - e) Antimigraine Agents
 - f) Electrolyte Depleters
 - g) Multiple Sclerosis Agents
 - h) CNS and Others
 - i. Agents for the Treatment of Opiate Addiction
- 6. New Business
- 7. Public Comment
- 8. Other Business
- 9. Adjourn